Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 11/20 | 0.38 |
| ▸ | CCND1 | P24385 | 10/20 | 0.38 |
| ▸ | CDK2 | P24941 | 8/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.34 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CCND3 | P30281 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.34 |
| ▸ | WEE1 | P30291 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15281056 | 0.87 | CDK4 (0.36) | CDK4CCND1CDK2FGFR1FGFR2 | |
| SCHEMBL15785356 | 0.75 | PAK1 (0.49) | — | |
| SCHEMBL15041689 | 0.75 | PAK3 (0.47) | WEE1 | |
| SCHEMBL16309201 | 0.74 | CAMK2D (0.44) | FGFR1FGFR2JAK3RIPK2NOD2 | |
| SCHEMBL15036103 | 0.74 | PAK3 (0.54) | CDK4CCND1CDK2JAK3CDK9 | |
| SCHEMBL13553643 | 0.73 | TNK2 (0.40) | CDK4CCND1CDK2FGFR1FGFR2 | |
| SCHEMBL15036027 | 0.73 | CDK9 (0.36) | CDK4CCND1CDK2FGFR1FGFR2 | |
| SCHEMBL15036083 | 0.73 | CCND1 (0.42) | CDK4CCND1CDK2FGFR1FGFR2 | |
| SCHEMBL15035857 | 0.70 | CDK4 (0.37) | CDK4CCND1CDK2FGFR1FGFR2 | |
| SCHEMBL15281078 | 0.70 | CDK4 (0.37) | CDK4CCND1CDK2FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CDK4 404/4885CCND1 2153/4885CDK2 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.